UBS Group
RMD icon

UBS Group’s ResMed RMD Stock Holding History

UBS Group’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$314K Hold
1,400
– – ﹤0.01% 6378
2025
Q4 		$337K Sell
1,400
-7,800
-85% -$1.99M ﹤0.01% 6290
2025
Q3 		$2.52M Buy
9,200
+1,400
+18% +$382K ﹤0.01% 4744
2025
Q2 		$2.01M Buy
7,800
+400
+5% +$95.4K ﹤0.01% 4812
2025
Q1 		$1.66M Buy
7,400
+2,600
+54% +$607K ﹤0.01% 4865
2024
Q4 		$1.1M Buy
+4,800
New +$1.16M ﹤0.01% 5230
2024
Q3 		– Sell
-69,300
Closed -$13.3M – 9978
2024
Q2 		$13.3M Sell
69,300
-15,700
-18% -$3.19M ﹤0.01% 2007
2024
Q1 		$16.8M Sell
85,000
-95,419
-53% -$17.5M ﹤0.01% 1830
2023
Q4 		$31M Buy
+180,419
New +$27.7M 0.01% 1284
2020
Q1 		– Sell
-5,600
Closed -$868K – 8330
2019
Q4 		$868K Sell
5,600
-2,000
-26% -$288K ﹤0.01% 4339
2019
Q3 		$1.03M Buy
+7,600
New +$996K ﹤0.01% 3945
2019
Q1 		– Sell
-2,300
Closed -$262K – 8091
2018
Q4 		$262K Buy
2,300
+1,200
+109% +$129K ﹤0.01% 4747
2018
Q3 		$127K Sell
1,100
-100
-8% -$11K ﹤0.01% 5378
2018
Q2 		$124K Buy
1,200
+1,000
+500% +$101K ﹤0.01% 5288
2018
Q1 		$20K Buy
+200
New +$18.9K ﹤0.01% 6416
2017
Q2 		– Sell
-130
Closed -$9K – 7930
2017
Q1 		$9K Sell
130
-800
-86% -$55.3K ﹤0.01% 6680
2016
Q4 		$58K Buy
+930
New +$57K ﹤0.01% 5707
2016
Q1 		– Sell
-100
Closed -$5K – 8078
2015
Q4 		$5K Sell
100
-2,000
-95% -$113K ﹤0.01% 7700
2015
Q3 		$107K Sell
2,100
-26,520
-93% -$1.43M ﹤0.01% 5182
2015
Q2 		$1.61M Buy
28,620
+28,520
+28,520% +$1.8M ﹤0.01% 3184
2015
Q1 		$7K Sell
100
-2,920
-97% -$190K ﹤0.01% 7918
2014
Q4 		$169K Buy
+3,020
New +$158K ﹤0.01% 5199

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group's RMD Position: Q1 2026 in Review

UBS Group reduced its ResMed (RMD) stake by 20% in Q1 2026, selling an estimated $44.8M and leaving 726,811 shares worth $163M. The position accounts for 0.02% of the portfolio, ranked #721.

UBS Group first reported a position in RMD in Q4 2014 and has held it in 46 quarters since. The position peaked at $239M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • UBS Group held 726,811 shares of ResMed worth $163M as of Q1 2026.
  • UBS Group sold 179,604 ResMed shares in Q1 2026, an estimated $44.8M.
  • ResMed made up 0.02% of UBS Group's portfolio in Q1 2026, its #721 holding.
  • UBS Group first reported a position in ResMed in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's ResMed position peaked at $239M in Q3 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.